4.4 Letter

Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: Comment on the article by Yoo

期刊

RHEUMATOLOGY INTERNATIONAL
卷 31, 期 6, 页码 841-842

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s00296-010-1485-3

关键词

Systemic sclerosis; Scleroderma; Rituximab; Interstitial lung disease; B cells; Fibrosis; Skin thickening; Rheumatic diseases

向作者/读者索取更多资源

Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据